Palatin Technologies (PTN)
(Delayed Data from AMEX)
$1.87 USD
-0.17 (-8.33%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1.87 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Brokerage Reports
Palatin Technologies, Inc. [PTN]
Reports for Purchase
Showing records 21 - 40 ( 197 total )
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
A Sight For Sore Eyes; PL9643 Exhibits Initial Pivotal Promise in DED; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
PL9588 Shows Initial Signs of Efficacy in Glaucoma Models; Vyleesi Traction Grows
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Important Preview: PL9643 Seeks to Strike the Right Chord in DED; MELODY-1 Top-Line Data Mid-23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2Q23 Results; DED and UC Top-Line Data in 2023 as MCR Platform Advances; Reiterate Top Pick
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Melanocortin Programs BREAKOUT With a New Phase 2 Trial in DKD; Top-Line Data in 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Interim F2Q23 Vyleesi Results; Sales and Prescriptions Keep Rising; Phase 3 MELODY-1 Data in 2Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F1Q23 Results; Melanocortin Platform Humming With Activity; MELODY-1 Topline Data in 2Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
All of Our Brains Should Look Like This; Impactful Vyleesi Effects Drive Excitement
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2022 Results; Melanocortin Receptor Therapies Progress in the Clinic; MELODY-1 Top-line Data in 2Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
PL8177 Moves to UC Phase 2; Data Readouts in 1H23; PT Adjusted to $70 Following Reverse Split
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MELODY-1 Gets the Green Light to Push On; Top-Line Results Expected in 2Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F3Q22 Results; Cash Strong and Driving Fast Toward Pivotal Dry Eye Data in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
PL9643 to Bring Tears of Joy; MELODY-1 Phase 3 Trial Proceeding as Planned
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2Q22 Results; Large Data Catalysts in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Melanocortin Platform Continues to Take Shape as PL9643 Pivotal Pushes Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
DED Program Goes Pivotal as Expected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Take Note of Breadth of Underlying Melanocortin Platform; Target Increased to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F1Q22 Results; Busy Times as PL9643 About to Go Pivotal
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2021 Results; Strong Pipeline of MCR Agonists Continue to Advance; DED Pivotal Starts Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J